by Sermonix Pharmaceuticals | Sep 5, 2023 | News
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an...
by Sermonix Pharmaceuticals | Jun 30, 2023 | News
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE...
by Sermonix Pharmaceuticals | Jun 26, 2023 | News
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patients The company is again partnering with Tempus to enroll patients in its Phase 3 ELAINE-3 study COLUMBUS, Ohio, June 26, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Jun 5, 2023 | News
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster...
by Sermonix Pharmaceuticals | May 26, 2023 | News
COLUMBUS, Ohio, May 25, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today shared...
Recent Comments